A Phase 1 Study of Intraperitoneal MCY-M11 Therapy for Women With Platinum Resistant High Grade Serous Adenocarcinoma of the Ovary, Primary Peritoneum, or Fallopian Tube, or Subjects With Peritoneal Mesothelioma With Recurrence After Prior Chemotherapy
Phase of Trial: Phase I
Latest Information Update: 24 Oct 2019
Price : $35 *
At a glance
- Drugs MCY-M11 (Primary)
- Indications Adenocarcinoma; Fallopian tube cancer; Mesothelioma; Ovarian cancer; Peritoneal cancer
- Focus Adverse reactions; First in man
- Sponsors MaxCyte
- 29 May 2019 According to a MaxCyte media release, this trial will be discussed in the company overview at the upcoming 2019 BIO International Convention on 5th June 2019.
- 08 May 2019 According to a MaxCyte media release, the company has completed patient dosing in first cohort and initiated dosing for the second cohort in this trial.
- 03 Apr 2019 Trial design presented at the 110th Annual Meeting of the American Association for Cancer Research.